Detail akcie Sana Biotech Rg online

Business Summary: Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Sana Biotechnology Inc revenues was not reported. Net loss decreased 15% to $185.3M. Lower net loss reflects Research & Development - Balancing value decrease of 47% to $42.3M (expense), Personnel decrease of 41% to $42.8M (expense), General and administrative - Balancing decrease of 28% to $25M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.96 to -$0.76.